RBC Capital Markets increased its price target on Celestica (NYSE:CLS) shares from $115.00 to $140.00 while maintaining an Outperform rating. Currently trading at $131.66, near its 52-week high, ...

Imposing higher capital requirements on UBS as a systemically relevant bank will usher in higher costs for companies and ...

UBS analyst Susy Tibaldi updated the financial outlook for EssilorLuxottica SA (EL:FP) (OTC: OTC:ESLOY), increasing the price ...

Bonnici was a managing director at RBC and led several high-profile deals across infrastructure and technology during his ...

RBC Capital analyst Kaan Peker maintained a Buy rating on Mineral Resources Limited (MALRF – Research Report) on January 30 and set a price ...

In a report released today, Nik Modi from RBC Capital maintained a Hold rating on Clorox (CLX – Research Report), with a price target of ...

Brian McGill and Michael Hyser operate as Johns Creek Financial along with support-staff members Stacie Alexander and Alexis ...

Street Talk understands Hong Kong’s Chow Tai Fook has tapped investment banks UBS and RBC Capital Markets for advice. How much Alinta’s owners are looking to part with is unclear, but Chow Tai ...

UBS Emerging Markets Equity Opp Fund earns an Average ... The investment seeks to maximize capital appreciation. Under normal circumstances, the fund invests at least 80% of its net assets ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target hoisted by equities researchers at UBS Group from $162.00 to $176.00 in a research note issued to investors on ...